Chikungunya-Dengue Co-Infection: Reports of Two Cases from Bangladesh

MA RAHIM a, S ZAMAN b, KN UDDIN c

Summary:
Chikungunya and dengue are the two most rapidly spreading mosquito-borne viral infections of global public health concern. Dengue is endemic in Bangladesh and here chikungunya is an emerging infection. Because of the spatio-temporal relationship between chikungunya virus and dengue virus, their co-existence and concurrent outbreaks are not unlikely. Here, we report two cases of chikungunya-dengue co-infections occurring among young Bangladeshi patients. Such co-infections need special attention because pain management of chikungunya may have adverse implications on patients with concurrent dengue infection.

Key words: Bangladesh, chikungunya, co-infection, dengue, sequential infection.

Introduction:
Chikungunya virus, dengue virus and their common vectors, Aedes spp. of mosquitoes are widely distributed throughout the world.1 Over the previous two decades, dengue has become established as an endemic disease in Bangladesh and an outbreak of chikungunya fever occurred in Dhaka, the capital of Bangladesh recently.2 In spite of widespread distribution of chikungunya virus, dengue virus and their vectors, co-infections by both the viruses are not that much common and such co-infection has only recently been reported from Bangladesh.1,3,4 We report two cases of chikungunya-dengue co-infection occurring among young Bangladeshi patients. Such co-infections are predicted to be increased in coming years in Bangladesh.5

Case Reports:

Case 1
A 19-year-old male presented with a 3-day history of fever, headache and generalized body ache. He had suffered a 5-day long febrile illness 2 weeks earlier. At that time, he had pain involving the feet, ankles and lower back. His fever responded to paracetamol but joint pain persisted even after the disappearance of fever. He was febrile (temp 102°F), tachycardic (pulse 104/min) and had a normal blood pressure (BP) (130/80 mm Hg). His haemoglobin was 12.8 g/dL, total and differential white cell counts and platelets were normal (TC 6,500/cmm, neutrophils 74%, lymphocytes 16%, platelets 1,85,000/cmm). Erythrocyte sedimentation rate (ESR) was 13 mm in 1st hour. Dengue nonstructural protein 1 (NS 1) [done by immunochromatographic test (ICT) by using commercially available kits manufactured by Humasis Co. Ltd., Republic of Korea] and anti-chikungunya immunoglobulin M (IgM) (done by ICT for chikungunya IgM/IgG by using commercially available kits manufactured by SD BIOSENSOR, Republic of Korea) were positive.

He was diagnosed as a case of chikungunya-dengue co-infection. He was on paracetamol and became afebrile on day 4 after fever onset but developed generalized maculopapular rash and pruritus that responded to fexofenadine. Because of persistent low back pain even after 3 months from the first onset of fever, he was put on sulphasalazine, though there was no radiological evidence of sacroilitis and his human leukocyte antigen (HLA) B27 report is awaiting.

Case 2
A 45-year-old male presented with high grade continued fever for 3 days. He had generalized aches and pains and two episodes of vomiting on day of consultation.
Three weeks back, he had suffered a febrile illness of 4 days duration. On day 3 of his first febrile illness, he developed generalized maculopapular rash along with pruritus. He took paracetamol and fexofenadine as per advice of local pharmacist.

Physical examination at our center revealed that, the patient had fever (103°F), dehydration, tachycardia (100/min) and low BP (100/70 mm Hg) without any postural drop. He had a normal haemogram (haemoglobin 11.3 g/dL, total white cells 7,300/cmm, platelets 2,10,000/cmm) with raised ESR (45 mm in 1st hour). NS 1 for dengue (ICT) and anti-chikungunya IgM (ICT) were positive.

He was treated with paracetamol, antiemetics and intravenous normal saline on 1st day of admission. He was discharged after 2 days in afebrile state.

**Discussion:**

Chikungunya and dengue are fast spreading infections and increasing numbers of international travels have largely contributed to this spread. Furuya-Kanamori L, *et al* in 2016 reported that among the 98 countries where both chikungunya and dengue were documented, only 13 countries (Figure 1) had chikungunya-dengue co-infections including Angola, Gabon, India, Madagascar, Malaysia, Myanmar, Nigeria, Saint Martin, Singapore, Sri Lanka, Tanzania, Thailand and Yemen. Such co-infections have also been reported from Bangladesh.3,4 As both dengue virus and chikungunya virus are transmitted by *Aedes* spp. of mosquitoes, co-infection or sequential infection by both are possible. Simultaneous presence of both the viruses have been demonstrated within the gut of same mosquito.7

Chikungunya and dengue are spacio-temporally related. They are common in clinical presentation and initial blood tests. Dengue NS 1 may detect dengue infection sufficiently early in disease course, real time reverse transcriptase polymerase chain reactions (RT-PCR) can identify chikungunya and dengue up to 5 days since fever onset, RT-PCR and serology should be done in 5-7 days and IgM against chikungunya and dengue appear in blood at the end first week or beginning of second week of fever onset and persist for weeks to months. While paracetamol remains as the mainstay of treatment for chikungunya and dengue viral infections during acute febrile phase, arthritis of chikungunya may require non-steroidal anti-inflammatory drugs (NSAIDS) which may increase the risk for haemorrhagic manifestation of dengue. So, during an outbreak, it is important to exclude dengue first rather than to establish the diagnosis of chikungunya fever.2

**Fig.-1:** The global distributions of endemic/epidemic dengue (top left) and chikungunya (top right) and reports of co-infection (bottom left) as well as the principal vectors of both arboviruses, *Aedes aegypti* and *Aedes albopictus* (bottom right) [Adopted from Furuya-Kanamori et al. BMC Infectious Diseases 2016;16:188]
Does co-infection by chikungunya virus and dengue virus adversely affect each other and the host? Different studies did not find worse patient outcome except one, where case fatalities occurred among elderly patients.1,8-10

**Conclusion:**
As chikungunya is an emerging viral infection in Bangladesh with variable clinical presentations, we emphasize that physicians should be aware of possible co-existence of chikungunya and dengue infections in coming years in appropriate clinical scenarios and during clinical management emphasis should be given to exclude dengue and care should be taken for to not use or minimize the use of NSAIDs in acute undifferentiated febrile illness.

**References:**